Furthermore, our selectivity analysis highlighted c‐Myc‐i7's impressive specificity for breast cancer and DU‐145 prostate cancer cells, emphasizing its potential as a promising therapeutic agent for these malignancies. Here, MYC is linked to prostate cancer.